Cargando…
Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers
BACKGROUND: Impaired myocardial blood flow (MBF) in the absence of epicardial coronary disease is a feature of hypertrophic cardiomyopathy (HCM). Although most evident in hypertrophied or scarred segments, reduced MBF can occur in apparently normal segments. We hypothesized that impaired MBF and myo...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475659/ https://www.ncbi.nlm.nih.gov/pubmed/34310159 http://dx.doi.org/10.1161/JAHA.120.020227 |
_version_ | 1784575449970507776 |
---|---|
author | Hughes, Rebecca K. Camaioni, Claudia Augusto, João B. Knott, Kristopher Quinn, Ellie Captur, Gabriella Seraphim, Andreas Joy, George Syrris, Petros Elliott, Perry M. Mohiddin, Saidi Kellman, Peter Xue, Hui Lopes, Luis R. Moon, James C. |
author_facet | Hughes, Rebecca K. Camaioni, Claudia Augusto, João B. Knott, Kristopher Quinn, Ellie Captur, Gabriella Seraphim, Andreas Joy, George Syrris, Petros Elliott, Perry M. Mohiddin, Saidi Kellman, Peter Xue, Hui Lopes, Luis R. Moon, James C. |
author_sort | Hughes, Rebecca K. |
collection | PubMed |
description | BACKGROUND: Impaired myocardial blood flow (MBF) in the absence of epicardial coronary disease is a feature of hypertrophic cardiomyopathy (HCM). Although most evident in hypertrophied or scarred segments, reduced MBF can occur in apparently normal segments. We hypothesized that impaired MBF and myocardial perfusion reserve, quantified using perfusion mapping cardiac magnetic resonance, might occur in the absence of overt left ventricular hypertrophy (LVH) and late gadolinium enhancement, in mutation carriers without LVH criteria for HCM (genotype‐positive, left ventricular hypertrophy‐negative). METHODS AND RESULTS: A single center, case‐control study investigated MBF and myocardial perfusion reserve (the ratio of MBF at stress:rest), along with other pre‐phenotypic features of HCM. Individuals with genotype‐positive, left ventricular hypertrophy‐negative (n=50) with likely pathogenic/pathogenic variants and no evidence of LVH, and matched controls (n=28) underwent cardiac magnetic resonance. Cardiac magnetic resonance identified LVH‐fulfilling criteria for HCM in 5 patients who were excluded. Individuals with genotype‐positive, left ventricular hypertrophy‐negative had longer indexed anterior mitral valve leaflet length (12.52±2.1 versus 11.55±1.6 mm/m(2), P=0.03), lower left ventricular end‐systolic volume (21.0±6.9 versus 26.7±6.2 mm/m(2), P≤0.005) and higher left ventricular ejection fraction (71.9±5.5 versus 65.8±4.4%, P≤0.005). Maximum wall thickness was not significantly different (9.03±1.95 versus 8.37±1.2 mm, P=0.075), and no subject had significant late gadolinium enhancement (minor right ventricle‒insertion point late gadolinium enhancement only). Perfusion mapping demonstrated visual perfusion defects in 9 (20%) carriers versus 0 controls (P=0.011). These were almost all septal or near right ventricle insertion points. Globally, myocardial perfusion reserve was lower in carriers (2.77±0.83 versus 3.24±0.63, P=0.009), with a subendocardial:subepicardial myocardial perfusion reserve gradient (2.55±0.75 versus 3.2±0.65, P=<0.005; 3.01±0.96 versus 3.47±0.75, P=0.026) but equivalent MBF (2.75±0.82 versus 2.65±0.69 mL/g per min, P=0.826). CONCLUSIONS: Regional and global impaired myocardial perfusion can occur in HCM mutation carriers, in the absence of significant hypertrophy or scarring. |
format | Online Article Text |
id | pubmed-8475659 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84756592021-10-01 Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers Hughes, Rebecca K. Camaioni, Claudia Augusto, João B. Knott, Kristopher Quinn, Ellie Captur, Gabriella Seraphim, Andreas Joy, George Syrris, Petros Elliott, Perry M. Mohiddin, Saidi Kellman, Peter Xue, Hui Lopes, Luis R. Moon, James C. J Am Heart Assoc Original Research BACKGROUND: Impaired myocardial blood flow (MBF) in the absence of epicardial coronary disease is a feature of hypertrophic cardiomyopathy (HCM). Although most evident in hypertrophied or scarred segments, reduced MBF can occur in apparently normal segments. We hypothesized that impaired MBF and myocardial perfusion reserve, quantified using perfusion mapping cardiac magnetic resonance, might occur in the absence of overt left ventricular hypertrophy (LVH) and late gadolinium enhancement, in mutation carriers without LVH criteria for HCM (genotype‐positive, left ventricular hypertrophy‐negative). METHODS AND RESULTS: A single center, case‐control study investigated MBF and myocardial perfusion reserve (the ratio of MBF at stress:rest), along with other pre‐phenotypic features of HCM. Individuals with genotype‐positive, left ventricular hypertrophy‐negative (n=50) with likely pathogenic/pathogenic variants and no evidence of LVH, and matched controls (n=28) underwent cardiac magnetic resonance. Cardiac magnetic resonance identified LVH‐fulfilling criteria for HCM in 5 patients who were excluded. Individuals with genotype‐positive, left ventricular hypertrophy‐negative had longer indexed anterior mitral valve leaflet length (12.52±2.1 versus 11.55±1.6 mm/m(2), P=0.03), lower left ventricular end‐systolic volume (21.0±6.9 versus 26.7±6.2 mm/m(2), P≤0.005) and higher left ventricular ejection fraction (71.9±5.5 versus 65.8±4.4%, P≤0.005). Maximum wall thickness was not significantly different (9.03±1.95 versus 8.37±1.2 mm, P=0.075), and no subject had significant late gadolinium enhancement (minor right ventricle‒insertion point late gadolinium enhancement only). Perfusion mapping demonstrated visual perfusion defects in 9 (20%) carriers versus 0 controls (P=0.011). These were almost all septal or near right ventricle insertion points. Globally, myocardial perfusion reserve was lower in carriers (2.77±0.83 versus 3.24±0.63, P=0.009), with a subendocardial:subepicardial myocardial perfusion reserve gradient (2.55±0.75 versus 3.2±0.65, P=<0.005; 3.01±0.96 versus 3.47±0.75, P=0.026) but equivalent MBF (2.75±0.82 versus 2.65±0.69 mL/g per min, P=0.826). CONCLUSIONS: Regional and global impaired myocardial perfusion can occur in HCM mutation carriers, in the absence of significant hypertrophy or scarring. John Wiley and Sons Inc. 2021-07-26 /pmc/articles/PMC8475659/ /pubmed/34310159 http://dx.doi.org/10.1161/JAHA.120.020227 Text en © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Hughes, Rebecca K. Camaioni, Claudia Augusto, João B. Knott, Kristopher Quinn, Ellie Captur, Gabriella Seraphim, Andreas Joy, George Syrris, Petros Elliott, Perry M. Mohiddin, Saidi Kellman, Peter Xue, Hui Lopes, Luis R. Moon, James C. Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers |
title | Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers |
title_full | Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers |
title_fullStr | Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers |
title_full_unstemmed | Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers |
title_short | Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers |
title_sort | myocardial perfusion defects in hypertrophic cardiomyopathy mutation carriers |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475659/ https://www.ncbi.nlm.nih.gov/pubmed/34310159 http://dx.doi.org/10.1161/JAHA.120.020227 |
work_keys_str_mv | AT hughesrebeccak myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers AT camaioniclaudia myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers AT augustojoaob myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers AT knottkristopher myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers AT quinnellie myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers AT capturgabriella myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers AT seraphimandreas myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers AT joygeorge myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers AT syrrispetros myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers AT elliottperrym myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers AT mohiddinsaidi myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers AT kellmanpeter myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers AT xuehui myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers AT lopesluisr myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers AT moonjamesc myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers |